TUESDAY, Sept. 2, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Leqembi Iqlik, a subcutaneous version of lecanemab, for weekly maintenance after the 18-month intravenous (IV) phase.
FRIDAY, Aug. 29, 2025 (HealthDay News) -- The U.S. Food and Drug Administration is now providing real-time, daily publication updates on adverse event data from its reporting system.
GoodRx reports that in 2025, novel drug and biosimilar approvals lag slightly behind last year, while first generic approvals are ahead.
GoodRx reports on identifying real Wegovy pens, which come in five colors and lack dose selectors. Counterfeits pose health risks; buy from trusted sources.
WEDNESDAY, July 2, 2025 (HealthDay News) -- The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity disorder (ADHD) medications, including certain formulations of amphetamine and methylphenidate, to warn about the medication's risk for weight loss and other adverse reactions in patients younger than 6 years of age.